Protein found in rheumatic diseases causes inflammation in COVID-19 patients

The sCD13 protein has been previously identified by a rheumatology research team at the University of Michigan as a powerful inducer of inflammation in multiple autoimmune disorders, such as rheumatoid arthritis and systemic sclerosis.

High levels of the sCD13 protein are also now being seen in blood and lung tissues of COVID-19 patients.

Researchers from University of Michigan Health, in collaboration with external institutions such as the NIH and Weill Cornell Medical School, have been able to identify this protein as a prominent cause of inflammation in the SARS-CoV-2 infection, more commonly known as COVID-19, using data sets from three separate cohorts of COVID-19 patients.

The work is published in the journal JCI Insight.

Formation of the sCD13 protein occurs by shedding of CD13 from the surface of certain types of cells, through a process that occurs in autoimmune disorders and as the body attempts to fight off the COVID-19 virus.

When this response is excessive, it is termed hyperinflammatory, and can exacerbate the severity of the disease.

The inflammatory response of increased amounts of sCD13 in COVID-19 patients is normally located in the lungs, where the virus levels are highest. Complications include respiratory failure requiring supplemental oxygen and mechanical ventilation. Additional complications include the formation of blood clots within small arteries of the lung.

These clots obstruct the flow of blood through the lung.

In some diseases, the formation of blood clots can be caused by NETs, neutrophil extracellular traps, which are sticky webs that are extruded by the neutrophil, a type of white blood cell.

In their research on sCD13 in COVID-19, the U-M Health researchers showed that sCD13 caused NET formation, following binding of sCD13 to two types of receptors on the surface of the neutrophil.

“In severe cases of COVID-19, this inflammation in the lungs can lead to acute respiratory distress syndrome, which causes difficulty breathing and can result in significant respiratory failure,” said Eliza Tsou, Ph.D., assistant professor of internal medicine at University of Michigan Health.

“When determining the severity of a COVID-19 infection, especially in patients that are experiencing extreme respiratory symptoms due to the virus, physicians can assess the level of sCD13 proteins as an indicator of the severity of the hyperinflammatory response within the patient.”

Tsou notes that evidence of the sCD13 protein impacting inflammation in COVID-19 also opens new avenues for treatment of the virus.

“The sCD13 protein and its receptors have emerged as new targets for treatment in pre-clinical trials for conditions such as rheumatoid arthritis and systemic sclerosis with success in animal models of these diseases,” said Tsou.

“As these treatment methods move into their clinical trials, it is important for researchers and providers to note that targeting the sCD13 protein also has a potential future role in the treatment of severe COVID-19 cases.”

The sCD13 protein has been previously identified by a rheumatology research team at the University of Michigan as a powerful inducer of inflammation in multiple autoimmune disorders, such as rheumatoid arthritis and systemic sclerosis.

High levels of the sCD13 protein are also now being seen in blood and lung tissues of COVID-19 patients.

Researchers from University of Michigan Health, in collaboration with external institutions such as the NIH and Weill Cornell Medical School, have been able to identify this protein as a prominent cause of inflammation in the SARS-CoV-2 infection, more commonly known as COVID-19, using data sets from three separate cohorts of COVID-19 patients.

The work is published in the journal JCI Insight.

Formation of the sCD13 protein occurs by shedding of CD13 from the surface of certain types of cells, through a process that occurs in autoimmune disorders and as the body attempts to fight off the COVID-19 virus.

When this response is excessive, it is termed hyperinflammatory, and can exacerbate the severity of the disease.

The inflammatory response of increased amounts of sCD13 in COVID-19 patients is normally located in the lungs, where the virus levels are highest. Complications include respiratory failure requiring supplemental oxygen and mechanical ventilation. Additional complications include the formation of blood clots within small arteries of the lung.

These clots obstruct the flow of blood through the lung.

In some diseases, the formation of blood clots can be caused by NETs, neutrophil extracellular traps, which are sticky webs that are extruded by the neutrophil, a type of white blood cell.

In their research on sCD13 in COVID-19, the U-M Health researchers showed that sCD13 caused NET formation, following binding of sCD13 to two types of receptors on the surface of the neutrophil.

“In severe cases of COVID-19, this inflammation in the lungs can lead to acute respiratory distress syndrome, which causes difficulty breathing and can result in significant respiratory failure,” said Eliza Tsou, Ph.D., assistant professor of internal medicine at University of Michigan Health.

“When determining the severity of a COVID-19 infection, especially in patients that are experiencing extreme respiratory symptoms due to the virus, physicians can assess the level of sCD13 proteins as an indicator of the severity of the hyperinflammatory response within the patient.”

Tsou notes that evidence of the sCD13 protein impacting inflammation in COVID-19 also opens new avenues for treatment of the virus.

“The sCD13 protein and its receptors have emerged as new targets for treatment in pre-clinical trials for conditions such as rheumatoid arthritis and systemic sclerosis with success in animal models of these diseases,” said Tsou.

“As these treatment methods move into their clinical trials, it is important for researchers and providers to note that targeting the sCD13 protein also has a potential future role in the treatment of severe COVID-19 cases.”